Fundraising FoxRevadix
Toulouse, FR · 1 known investors
Find your way into Revadix
Sign up to see every warm intro you have to Revadix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Revadix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.
Founders & leadership
FL
Frank Lezoualc'hScientific Founder / Research Director at Inserm
Investors · 1
NLClisted by NLCAmsterdam
How we know: NLC's portfolio page · Not right? Tell us
Frequently asked questions
- What does Revadix do?
- Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.
- Who founded Revadix?
- Revadix was founded by Frank Lezoualc'h.
- Who are Revadix's investors?
- Revadix's investors include NLC.
- Where is Revadix headquartered?
- Revadix is headquartered in Toulouse, FR.